A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The aim of the present study was to explore the effects of various combinations of exenatide, metformin (MET) and biphasic insulin aspart 30 (BIA30) on type 2 diabetes mellitus (T2DM). Two hundred overweight or obese patients newly diagnosed with T2DM were evenly randomized into two groups: A (twice daily for all: Phase I, 5 µg exenatide + 0.5 g MET for 4 weeks, then 10 µg exenatide + 0.5 g MET for 8 weeks; Phase II, 0.5 g MET for 12 weeks; Phase III, 0.3-0.4 U/kg/day BIA30 + 0.5 g MET for 12 weeks) and B (Phases I, II, III matched the phases III, II and I in group A). In groups A and B a significant decrease and increase, respectively, in glycated hemoglobin (HbAlc) and body mass index (BMI) was noted during Phase I. A 3.2±0.4-kg decrease in body weight in group A and a 2.6±0.3-kg increase in group B was observed. In Phase II, HbAlc was significantly increased in both groups (P<0.05). In Phase III, the BMI was increased in group A and reduced in group B (P<0.05). There was a 3.8±0.4-kg weight decrease in group B and 4.2±0.5-kg increase in group A (P<0.05). The combination of exenatide and MET promoted weight loss, glycemic control, β-cell function index, C peptide and adiponectin levels. These results suggested that the combination of exenatide and MET is better than the combination of BIA and MET for the therapy of overweight or obese patients newly diagnosed with T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“Exenatide has been shown to improve glycemic control in patients with T2DM who failed to achieve glycemic control with maximally effective MET doses (29).”
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“GLP-1 has been proposed for the treatment of T2DM patients; however, native GLP-1 can be degraded within 2-3 min (4).”
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Engelgau, M. M., Thompson, T. J., Herman, W. H., Boyle, J. P., Aubert, R. E., Kenny, S. J., Badran, A., Sous, E. S., & Ali, M. A. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.785 · Cited by 325
Shao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185 · cited 1×
“Although the antidiabetic activity of exenatide has been widely reported (9-11), a combined therapy promotes insulin secretion and insulin sensitivity in new-onset T2DM patients to produce a greater, more durable reduction in glycated haemoglobin (HbA1c) levels compared with mono-therapy (12).”
Derosa, G., Franzetti, I. G., Querci, F., Carbone, A., Ciccarelli, L., Piccinni, M. N., Fogari, E., & Maffioli, P. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03699.x · Cited by 70
Research works printed but not linked: 28
- Lewis, 2014, Patients' perspectives of care for type 2 diabetes in Bangladesh-a qualitative study, BMC Public Health, 14, 737, 10.1186/1471-2458-14-737 · DOI
- Wang, 2014, Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists, J Diabetes, 6, 164, 10.1111/1753-0407.12077 · doi:10.1111/1753-0407.12077
- Umpierrez, 2013, Reshaping diabetes care: The fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice, Endocr Pract, 19, 718, 10.4158/EP12292.RA · DOI
- Marchetti, 2009, Autophagy and the pancreatic beta-cell in human type 2 diabetes, Autophagy, 5, 1055, 10.4161/auto.5.7.9511 · DOI · Paper page
- Rosenstock, 2012, Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes, Diabetes Care, 35, 955, 10.2337/dc11-1434 · DOI · Paper page
- Anderson, 2014, Exenatide extended-release: A once-weekly option for patients with type 2 diabetes, JAAPA, 27, 44, 10.1097/01.JAA.0000443811.42907.a5 · DOI
- Carrington, 2014, Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: A retrospective study from a specialist diabetes outpatient clinic, Intern Med J, 44, 345, 10.1111/imj.12377 · DOI
- Abdul-Ghani, 2015, Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT): A randomized trial, Diabetes Obes Metab, 17, 268, 10.1111/dom.12417 · DOI · Paper page
- Almansari, 2014, Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: Results from the Gulf cohort of the A1 chieve study, Int J Clin Pract, 68, 850, 10.1111/ijcp.12391 · doi:10.1111/ijcp.12391
- Bergenstal, 2009, NovoLog Mix-vs.-Exenatide Study Group: Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea, Curr Med Res Opin, 25, 65, 10.1185/03007990802597951 · DOI · Paper page
- Yang, 2009, Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents, Chin Med J (Engl), 122, 1704
- Davidson, 2009, Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: A meta-analysis, Clin Ther, 31, 1641, 10.1016/j.clinthera.2009.08.011 · DOI
- 2009, American Diabetes Association: Standards of medical care in diabetes-2009, Diabetes Care, 32, S13, 10.2337/dc09-S013 · DOI · Paper page
- Kim, 2010, Triple combination therapy using metformin, thiazolidinedione and a GLP-1 analog or DPP-IV inhibitor in patients with type 2 diabetes mellitus, Korean Diabetes J, 34, 331, 10.4093/kdj.2010.34.6.331 · DOI
- Kann, 2006, Starting insulin therapy in type 2 diabetes: Twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride, Exp Clin Endocrinol Diabetes, 114, 527, 10.1055/s-2006-949655 · DOI · Paper page
- 2014, General Assembly of the World Medical Association: World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects, J Am Coll Dent, 81, 14
- Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 · DOI · Paper page
- Steppan, 2001, The hormone resistin links obesity to diabetes, Nature, 409, 307, 10.1038/35053000 · DOI · Paper page
- Yamamoto, 2013, Association between reduction of plasma adiponectin levels and risk of bacterial infection after gastric cancer surgery, PloS One, 8, e56129, 10.1371/journal.pone.0056129 · DOI
- Shehzad, 2012, Adiponectin: Regulation of its production and its role in human diseases, Hormones (Athens), 11, 8, 10.1007/BF03401534 · DOI · Paper page
- Freeman, 2002, West of Scotland Coronary Prevention Study: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland coronary prevention study, Diabetes, 51, 1596, 10.2337/diabetes.51.5.1596 · DOI · Paper page
- Xu, 2002, Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity, Diabetes, 51, 1876, 10.2337/diabetes.51.6.1876 · DOI · Paper page
- Frias, 2016, Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): A 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4: 1004–1016, 2016, Lancet Diabetes Endocrinol, 4, 1004, 10.1016/S2213-8587(16)30267-4 · DOI · Paper page
- Mohammadzadeh, 2011, Hypoadiponectinemia in obese subjects with type II diabetes: A close association with central obesity indices, J Res Med Sci, 16, 713
- Vimaleswaran, 2008, A novel association of a polymorphism in the first intron of adiponectin gene with type 2 diabetes, obesity and hypoadiponectinemia in Asian Indians, Human Genet, 123, 599, 10.1007/s00439-008-0506-8 · DOI
- Weyer, 2001, Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia, J Clin Endocrinol Metab, 86, 1930, 10.1210/jcem.86.5.7463 · DOI · Paper page
- Weise, 2009, Exenatide-associated ischemic renal failure, Diabetes Care, 32, e22, 10.2337/dc08-1309 · DOI · Paper page
- Barnett, 2007, Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 29: 2333–2348, 2007, Clin Ther, 29, 2333, 10.1016/j.clinthera.2007.11.006 · DOI · Paper page
Cited by
Bray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194
“They comprised 6749 patients (inflammation evaluated in 6560, oxidative stress in 701 patients), included a median (IQR) study population of 60 (33-122) participants, and had a median (IQR) follow-up of 6 months (84-182 days).”
BackgroundRen, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59
Zhao, F., Wang, H., Li, S., Yun, H., & Su, W. (2026) · PeerJ · doi:10.7717/peerj.20710 · Cited by 6
“…(2016) ; Bunck et al. (2010) ; Derosa et al. (2010) ; Forst et al. (2012) ; Li et al. (2019) ; Lin et al. (2015) ; Pastel et al. (2017) ; Quan et al. (2017) ; Shao et al. (2024) ; Shi et al. (2017) ; Wu et al. (2011) ; Gurkan et al. (2014) ; Ahmad et al. (2021) ; Derosa et al. (2011) ;…”
Kanbay, M., Shah, E., AlShiab, R., Ozbek, L., Ay, S., Rustamov, A., Covic, A., Mallamaci, F., & Zoccali, C. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.71106 · Cited by 4
Alrasheed, T., Mostafa, M. E. A., Madkhali, M. A., & Khairy, H. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1734549 · Cited by 4
Metadata
- Authors
- Quan, H., Zhang, H., Wei, W., Fang, T., Chen, D., & Chen, K.
- Venue
- Experimental and Therapeutic Medicine
- Publisher
- Spandidos Publications
- Published
- 2017-08-02
- Volume
- 14
- Issue
- 4
- Pages
- 3279-3287
- ISSN
- 1792-0981 (ISSN-L)
- 1792-1015
- OpenAlex
- W2740178513
- Cited by
- 13
- References
- 7
- FWCI
- 0.19
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.